Cidara Therapeutics, Inc. (CDTX) Stock Analysis & Investment Frameworks

Cidara Therapeutics, Inc. (CDTX) stock analysis on Invetso. Review Cidara Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Cidara Therapeutics, Inc. Company Overview

Cidara Therapeutics, Inc. Key Financial Metrics

About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.

Cidara Therapeutics, Inc. Investment Frameworks

Invetso analyzes Cidara Therapeutics, Inc. (CDTX) across the following frameworks:

Explore More CDTX Research